News
Combination exhibits ‘impressive’ activity in HPV-negative head and neck cancer
“HPV-negative disease is one aera of head and neck cancer where we haven’t made much progress,” investigator Barbara Burtness, MD, chief translational research officer for Yale Cancer Center and Smilow Cancer Hospital, as well as associate cancer center director for translational research at Yale Cancer Center, told Healio. “These cancers respond to chemotherapy and EGFR inhibitors, but the duration of response has not been great.
“There has been a breakthrough with the introduction of immune checkpoint inhibitors, but the majority of patients progress on those as well,” added Burtness, a Healio | HemOnc Today Editorial Board Member. “When we move into late lines of therapy, not many agents have shown promise. That’s one of the reasons people are so excited about this study.”
Source: Healio